News General

Hepatitis: Still a Global Health Issue

April 19, 2021 - Spain

One of the major causes of acute and chronic liver diseases is infection by the Hepatitis B and C viruses (HBV and HCV respectively). Both are blood-borne viruses and therefore their transmission occurs due to exposure to infected blood or bodily fluids containing blood. It is estimated that HBV and HCV infections cause 1.4 million deaths annually1.

It is estimated that around 248 million people worldwide are living with chronic HBV infection while 110 million people worldwide are HCV positive. The highest HBV prevalence is in the Asia-Pacific and Africa regions with an estimated prevalence in the adult population of 6.2% and 6.1%, respectively2. For HCV infection, the prevalence is highest in the Eastern Mediterranean and European regions with an estimated incidence in the adult population of 2.3% and 1.5%, respectively3.

Although HBV vaccination campaigns and improved treatments for HBV and HCV have played a key role in controlling the spread of these viruses, these infections are still a global healthcare issue.

Hepatitis: Still a Global Health Issue

 

Hepatitis is a global health issue that is leading to an increase in the demand for Hepatitis immunoassays. Are you ready for that?

If you are expecting an increase in demand for your HBV and/or HCV assays, or you envision a new generation of these immunoassays in your portfolio, we can help you with Biokit Hepatitis B and C Biomaterials. Our Biomaterials are playing a key role in the commercial and clinical success of various IVD assays in the chemiluminescence format.

When used in commercial chemiluminescence IVD assays, Biokit Hepatitis B and C Biomaterials have demonstrated the following performance:

 

Commercial IVD Assay 

Sensitivity 

Specificity 

Hepatitis B 

Hepatitis B surface Antigen (HBsAg) 

100% 

n=537* 

99.06% 

n=5,181 

Hepatitis B core Antigen (HBcAg) 

100% 

n=403* and n=203* 

99.9% 

n=5,097 

Hepatitis B surface Antigen Antibodies (anti-HBs) 

99.0% 

n=349 

100% 

n=349 

Hepatitis C 

Hepatitis C IgG Antibody (anti-HCV) 

100% 

n=704* 

99.7% 

n=5,022 

*Positive samples from various sources. Samples from blood donors.Sample population.

 

Biokit Hepatitis biomaterials portfolio consists of the following products:

 

Biomaterial

Description

PN

Hepatitis B 

Antigens

Hepatitis B Surface Antigen (ad subtype)

3000-5201

Hepatitis B Surface Antigen (ay subtype)

3000-5199

Recombinant HBs Antigen (ad subtype)

3000-5269

Recombinant HBc Antigen

3000-5100

Antibodies

Anti-HBs Goat IgG pAb

3000-5501

Anti-HBs Guinea Pig IgG pAb

3000-5264

Anti-HBs mAb IgG

3000-5012

Hepatitis C 

Antigens

Recombinant HCV Capsid Polypeptide

3000-5103

Recombinant HCV NS3 Polypeptide

3000-5104

 

Sources: 1WHO (World Health Organization). WHO Guidelines on Hepatitis B and C Testing [Internet]. Geneva: WHO; 2017 Feb. 204 p. [cited 2018 May 23]. Available from: http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/; 2World Health Organization (WHO). Hepatitis B [Internet]. Geneva: WHO; 2019 Jul 18. (Fact sheets; ). [cited 2020 Mar 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b; 3World Health Organization (WHO). Hepatitis B [Internet]. Geneva: WHO; 2019 Jul 18. (Fact sheets; ). [cited 2020 Mar 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

Share Press Release:

LinkedIn twitter facebook

Contact us


Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

Data protection policy
Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy (link). You can also contact us at DPO-biokit@werfen.com.